Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.
Original Article: Liu Lends Insight on Acquired Resistance in Oncogene-Driven NSCLC